Will the CanSinoBio vaccine be considered safe and effective against Covid-19 by the end of July 2021?
Market Rules
By October 2020, at least 140 vaccine candidates against SARS-CoV-2 were currently being developed, with 54 of them in human trials, and 11 of them in Phase III, when the vaccine needs to prove that it is capable of protecting the target population from getting the infection.
The vaccine that was created by the Chinese company CanSinoBio is a vaccine made mainly of an Adenovirus vector (Ad5). The vaccine is in Phase III in China, Saudi Arabia, Pakistan, and Russia. The China military has approved it for limited use in military personnel.
If the results from phase III of the CanSinoBio vaccine trials are released by July 31, 2021, and the international scientific community considers that they prove that the CanSinoBio vaccine is indeed safe and effective against COVID-19, this market will be resolved as "Yes". Alternatively, this market may also be resolved as "Yes" if the vaccine is approved by at least one of the following agencies before that: ANVISA (Brazil), FDA (USA or EMA (European Union).
This market will be resolved based on news (with verifiable sources) and scientific studies on the subject from sources or publications that Futuur finds credible and reputable, such as, but not restricted to, World Health Organization, Nature Magazine, Science and other specialized scientific journals.